

ISSUE @ A GLANCE



How to slice the pie: heart failure subgroups and their clinical meaning

T.F. Lüscher

2339

CardioPulse

William T. Abraham, MD

J. Ozkan

2344

The ESC Working Group on Myocardial Function

T. Thum

2346

The Swiss Society of Cardiology

G. Pedrazzini and M. Rüdiger-Stürchler

2348

Maurizio Galderisi (31 August 1954-27 March 2020)

T. Edvardsen, B. Cosyns, B.A. Popescu, and G. Maurer

2350

A personal tribute to Maurizio Galderisi

E. Barbato

2351

VIEWPOINT

Heart failure/cardiomyopathy

Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction

C.S. P. Lam, A.A. Voors, P. Piotr, J.J.V. McMurray, and S.D. Solomon

2353

FAST TRACK CLINICAL RESEARCH

ACC.20

A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction

M. Vaduganathan, P.S. Jhund, B.L. Claggett, M. Packer, J. Widimský, P. Seferovic, A. Rizkala, M. Lefkowitz, V. Shi, J.J.V. McMurray, and S.D. Solomon

2356

Editorial

Ejection fraction in heart failure revisited- where does the evidence start?

M. Böhm, Y. Bewar, and I. Kindermann

2363

Hypertensive coronary microvascular dysfunction: a subclinical marker of end organ damage and heart failure

W. Zhou, J.M. Brown, N.S. Bajaj, A. Chandra, S. Divakaran, B. Weber, C.F. Bibbo, J. Hainer, V.R. Taqueti, S. Dorbala, R. Blankstein, D. Adler, P. O'Gara, and M.F. Di Carli

2366

Editorial

Coronary microcirculation and hypertensive heart failure


J. Escaned and L.O. Lerman

2376

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy

K.F. Docherty, P.S. Jhund, S.E. Inzucchi, L. Køber, M.N. Kosiborod, F.A. Martinez, P. Ponikowski, D.L. DeMets, M.S. Sabatine, O. Bengtsson, M. Sjöstrand, A.M. Langkilde, A.S. Desai, M. Diez, J.G. Howlett, T. Katova, C.E.A. Ljungman, E. O'Meara, M.C. Petrie, M. Schou, S. Verma, P.N. Vinh, S.D. Solomon, and J.J.V. McMurray; on behalf of the DAPA-HF Investigators and Committees

2379



Editorial

Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care

M. Packer

2393


CLINICAL REVIEW

Controversies in cardiovascular medicine

A realistic appraisal of the use of embryonic stem cell-based therapies for cardiac repair

M. Wysoczynski and R. Bolli

2397



CURRENT OPINION

Myocardial disease

Living myocardial slices: a novel multicellular model for cardiac translational research

F. Perbellini and T. Thum

2405

DISCUSSION FORUM

Intravenous vasodilators in acute heart failure patients with low basic blood pressure: may the benefit come from targeting perfusion rather than pressure?

P.P. Bocchino, F. Angelini, and S. Frea

2409

Does hypoperfusion outperform blood pressure as a better predictor in the risk stratification of acute heart failure?

Y. Zhou, F. Liu, and J. Nie

2411

CARDIOVASCULAR FLASHLIGHTS

A novel transcatheter technique to treat of post-coarctation aneurysm with device occlusion of the aortic arch and descending aorta in a patient with an extra-anatomic bypass

V. Pascual-Tejerina, A. Sánchez-Recalde, G. Garzón, and J.L. Zamorano

2412

Hot hearts on bone scintigraphy are not all amyloidosis: hydroxychloroquine-induced restrictive cardiomyopathy

M.E. Layoun, J. Desmarais, S.B. Heitner, and A. Masri

2414

Brown adipose tissue activation in severe heart failure

A. Tahara, N. Tahara, S. Maeda-Ogata, M. Bekki, Y. Sugiyama, A. Honda, T. Abe, S.-I. Yamagishi, and Y. Fukumoto

2415

Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site
<https://academic.oup.com/eurheartj>



www.eurheartj.org